about
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practiceFrench Intensive Care Society, International congress - Réanimation 2016A simulation procedure based on copulas to generate clustered multi-state survival data.Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.Testing the treatment effect on competing causes of death in oncology clinical trialsA Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models.Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces.Incorporation of nested frailties into semiparametric multi-state models.Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.Prediction of treatment benefit in high-dimensional cox models via gene signatures in randomized clinical trials.biospear: an R package for biomarker selection in penalized Cox regression.Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach.First-line treatment in metastatic colorectal cancer: Important or crucial?Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trialsQuelles exigences pour qu'un biomarqueur puisse être un critère de substitution acceptable ?
P50
Q28078729-28D4ED6C-23E7-4FA2-99C6-A6A0120F21A7Q28550357-8B538C0E-5450-4FD1-AEF7-F9EB528BAA6DQ30574746-1ECD49B9-D41D-4FEB-B2A4-6B6A82E86DFDQ31064714-4CADA1C9-417A-4EF7-849D-92CABB9BD80AQ33717226-87A55503-5874-4944-9C22-6B077CEA8ED2Q35177617-61D997CE-B8B2-4470-90E3-663A34FD020EQ38691539-DDD694B3-A50B-4ECE-85DB-9D116683E380Q38771327-1ECFEA28-20B3-47C5-8D87-7A146F5ADBBFQ39175273-2057DE2B-90F5-4DAE-97D4-86BDED2F435EQ40528310-FFBB8784-D3DA-466F-8C97-0E1BD4F3ACF4Q42701270-8579ABBA-00D3-4850-91ED-3303CF9371FDQ45983846-77ADFD86-70E5-4C79-B0E8-B28F15EB17B2Q47960310-C0BAF815-B4CA-4F2C-841F-59523FFF3C0CQ48561327-F76BF613-FF69-4AD6-A7FD-BC99EAA107B5Q49886827-17C830E2-9287-4988-9A20-B062C595425EQ55285332-EBD78CA5-6536-4BB2-89E3-CF1267C91E42Q62785334-5C350A55-52C3-41A1-914E-88CE27AFEA48Q62785370-16735D97-A096-4D91-8ACF-13F36F676F09
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Federico Rotolo
@ast
Federico Rotolo
@en
Federico Rotolo
@es
Federico Rotolo
@nl
Federico Rotolo
@sl
type
label
Federico Rotolo
@ast
Federico Rotolo
@en
Federico Rotolo
@es
Federico Rotolo
@nl
Federico Rotolo
@sl
prefLabel
Federico Rotolo
@ast
Federico Rotolo
@en
Federico Rotolo
@es
Federico Rotolo
@nl
Federico Rotolo
@sl
P1053
D-4567-2016
P106
P1153
55414389900
P21
P2456
P31
P3829
P496
0000-0003-4837-6501